Strain Data Sheet

RBRC04021

Strain Information

Image
BRC No.RBRC04021
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6.129-Dnase2a<tm1Osa> Ifnar1<tm1Agt>
Former Common nameDNaseII / IFN-IR double knock out
H-2 Haplotype
ES Cell lineR1 [(129X1/SvJ x 129S1/Sv)F1-Kitl<+>]
Background strainC57BL/6
Appearance
Strain developmentDeveloped by Kohki Kawane and Shigekazu Nagata, Graduate School of Medicine, Kyoto University in 2004. C57BL/6 background (over N8 generations).
Strain descriptionDNaseII/IFN-IR double knockout mice. Double homozygous mutant mice develop polyarthritis as age.
Colony maintenanceDnase2a: Heterozygote x Wild-type; Ifnar1: Homozygote x Homozygote
References
Functional role of type I and type II interferons in antiviral defense.
Muller U, Steinhoff U, Reis L F, Hemmi S, Pavlovic J, Zinkernagel R M, Aguet M
Science, 264, 1918-1921 (1994). 8009221

Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA.
Yoshida H, Okabe Y, Kawane K, Fukuyama H, Nagata S
Nat. Immunol., 6, 49-56 (2005). 15568025

Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages.
Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, Yoshikawa H, Nagata S
Nature, 443, 998-1002 (2006). 17066036

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Ifnar1
MGI:107658		interferon (alpha and beta) receptor 116Ifnar1<tm1Agt>
MGI:1930950		targeted mutation 1, Michel Aguet
neo neomycin resistance gene (E. coli)16 herpes simplex virus thymidine kinase promoter (HSV tk promoter)
Dnase2a
MGI:1329019		deoxyribonuclease II alpha8Dnase2a<tm1Osa>
MGI:2449811		targeted mutation 1, Shigekazu Nagata
loxP phage P1 loxP8loxP
neo neomycin resistance gene (E. coli)8 mouse phosphoglycerate kinase promoter (PGK promoter)

Phenotype

Annotation by Mammalian phenotyhpe ontology
  • abnormal CD8-positive, alpha-beta T cell physiology(MP:0004392)

  • abnormal NK cell physiology(MP:0010766)

  • abnormal blood homeostasis(MP:0009642)

  • abnormal cytokine level(MP:0008713)

  • abnormal cytokine secretion(MP:0003009)
    • more 38 phenotypes
  • abnormal dendritic cell physiology(MP:0002376)

  • abnormal erythropoiesis(MP:0000245)

  • abnormal immunoglobulin level(MP:0002490)

  • abnormal inflammatory response(MP:0001845)

  • abnormal interferon-gamma secretion(MP:0008559)

  • abnormal macrophage morphology(MP:0002446)

  • abnormal osteoclast morphology(MP:0004982)

  • abnormal response to infection(MP:0005025)

  • abnormal susceptibility to infection(MP:0001793)

  • abnormal thymus morphology(MP:0000703)

  • anemia(MP:0001577)

  • cornea vascularization(MP:0005542)

  • decreased bone mineral density(MP:0000063)

  • decreased erythrocyte cell number(MP:0002875)

  • decreased interferon-alpha secretion(MP:0008563)

  • decreased interferon-beta secretion(MP:0008565)

  • decreased interleukin-6 secretion(MP:0008706)

  • decreased susceptibility to viral infection induced morbidity/mortality(MP:0009790)

  • decreased susceptibility to viral infection(MP:0002410)

  • decreased tumor necrosis factor secretion(MP:0008561)

  • enlarged spleen(MP:0000691)

  • impaired natural killer cell mediated cytotoxicity(MP:0005070)

  • increased circulating interleukin-12 level(MP:0008617)

  • increased circulating interleukin-18 level(MP:0008635)

  • increased circulating tumor necrosis factor level(MP:0008553)

  • increased nucleated erythrocyte cell number(MP:0009395)

  • increased spleen red pulp amount(MP:0008476)

  • increased susceptibility to bacterial infection induced morbidity/mortality(MP:0009788)

  • increased susceptibility to viral infection induced morbidity/mortality(MP:0009791)

  • increased susceptibility to viral infection(MP:0002418)

  • increased tumor growth/size(MP:0003721)

  • joint inflammation(MP:0002933)

  • lethality during fetal growth through weaning, complete penetrance(MP:0011111)

  • postnatal growth retardation(MP:0001732)

  • reproductive system phenotype(MP:0005389)

  • rheumatoid arthritis(MP:0003561)

  • small thymus(MP:0000706)

  • thymus hypoplasia(MP:0001823)
    • Detailed phenotype data

    Ordering Information

    Donor DNABacteriophage P1 loxP sequence, Mouse Pgk1 genomic DNA, E. coli Neomycin resistance gene, mouse Dnase2a genomic DNA, Herpes simplex virus Thymidine kinase promoter (HSV-tk promoter), Polyoma virus genomic DNA, mouse Ifnar1 genomic DNA [update March 10, 2014]
    Research applicationCre/loxP system
    Immunology and Inflammation Research
    Mouse Models for Human Disease
    Specific Term and ConditionsThe RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Nature, 443, 998-1002 (2006). Nat. Immunol., 6, 49-56 (2005). RECIPIENT may only use the BIOLOGICAL RESOURCE for non-commercial academic research purpose. The RECIPIENT should negotiate with the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE.
    DepositorShigekazu Nagata (Osaka University)
    Strain Statusan icon for Frozen embryosFrozen embryos
    an icon for Frozen spermFrozen sperm
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved sperm (within 1 month)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
    4. Acceptance of responsibility for living modified organism (Japanese / English)
    Lab HP
    Genotyping protocol -PCR-
    Mouse of the Month Aug 2012

    BRC mice in Publications

    Yoshikawa R, Sakabe S, Urata S, Yasuda J.
    Species-Specific Pathogenicity of Severe Fever with Thrombocytopenia Syndrome Virus Is Determined by Anti-STAT2 Activity of NSs.
    J Virol 93(10) (2019) 30814285